Neuland Laboratories Ltd Q3 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/q112nvpvv6q25z4ql3qnzj0e.pdf

Key Takeaways


CMS Business: The Margin Driver

Saharsh Davuluri: "the only caveat I would add is because these are new drugs there is always a risk that the drug may not get approved or there is also a risk that the drug may not be successful. So therefore we are still very cautious"

Margin Composition & Variability

Saharsh Davuluri: "I think it is hard to give you more granularity on how the gross margins will figure out, but I think what we are seeing is a good blend right now and unless there is a crazy surge in raw materials or maybe big fluctuation in forex. These margins are a reasonable baseline for now to take..."

Unit 3 & Capacity

Saharsh Davuluri: "I think decisions to expand will be based on what we figure out in the next six months or so. But I think definitely as a growing company we will have to make sure that R&D resources do not limit our ability to scale up more and more projects."

Specialty & Prime Segments


Balance Sheet & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Unit 3 profitabilityUnit 3 expected to turn profitableUpcoming quarter (Q4 FY23)
Unit 3 utilizationMove closer to 68-69% utilizationFY24
CMS molecule commercializationExpect maybe a couple more CMS molecules to commercialize; cumulatively should be goodNext one to two years
CMS business growthGood healthy growth and profitability from CMS businessNext three to five years
Capex run-rateTrending around ₹100 Crores per year for maintenance plus upgradesOngoing
R&D expansion decisionDecision on whether to expand R&D capacityNext six months
Gross margin baselineCurrent gross margins are a reasonable baseline, absent raw-material surge or big forex fluctuationOngoing, with stated caveats
ROCE rangeSustain in the broad range of 17 to 20%Ongoing

Key Metrics

MetricQ3 FY23
Gross margin55.2%, compared to 49.2% in Q3 FY22 and 56.2% in Q2 FY23
Profit after tax₹30.4 cr, compared to ₹12.7 cr in Q3 FY22
EPS₹23.7 per share
9M FY23 total income₹785.8 cr, an increase of 12.3% over 9M FY22
9M FY23 EBITDA₹153.3 cr, an increase of 46.1% over 9M FY22
9M FY23 EBITDA margin19.5%, compared to 15% in 9M FY22
9M FY23 free cash flow₹161 cr
Net debt₹72 cr as of December 2022, reduced from ₹212 cr as of March 2022
Net gearing ratio0.1x as of December 2022
9M FY23 capex₹50.9 cr
CMS business revenue share35%–40% of total revenues
Unit 1 and Unit 2 capacity utilization80%–85%, depending on quarter and product mix
Unit 3 capacity utilization~65% based on installed capacity; FY23 estimate 62%–65%, FY24 forecast 68%–69%
CMS commercial launch revenue~₹75 cr this quarter, up from an average of ₹40–50 cr over the prior four quarters
Procurement from China~25% of procurement, though dependence on China is far less
ROCE target17%–20% broad range
R&D scientists360–370 currently operating